MRT-6160

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is leveraging its proprietary QuEEN™ discovery engine to create a new class of small molecule medicines called molecular glue degraders, which harness the body's natural protein degradation machinery to eliminate specific disease-driving proteins. The company's lead program, MRT-2359, is a potent, selective degrader of GSPT1 and is being evaluated in a Phase 1/2 trial for MYC-driven solid tumors and lymphomas. With a strong leadership team, strategic partnerships, and a deep pipeline of preclinical programs, Monte Rosa aims to address significant unmet medical needs in oncology and beyond by targeting proteins that have historically been considered undruggable.

Therapeutic Areas